eik1001
·Code: BDB001
eik1001: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Eikon Therapeutics Inc. (EIKN) | Phase 2/Phase 3 |
Clinical Trials (1)
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).
Frequently asked questions
Who is developing eik1001?
eik1001 is being developed by Eikon Therapeutics Inc..
How many clinical trials involve eik1001?
BioSniper tracks 1 clinical trial involving eik1001.
Get deeper analysis on eik1001
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis